{"DataElement":{"publicId":"4379842","version":"1","preferredName":"Blood Coagulation Assessment  Code Indicator","preferredDefinition":"The coded yes/no/not applicable indicator related to assessment of clot formation in blood.","longName":"LAB_BLD_COAG_COD_IND","context":"Theradex","contextVersion":"1","DataElementConcept":{"publicId":"3121732","version":"1","preferredName":"Blood Coagulation Assessment","preferredDefinition":"information related to assessment of clot formation in blood.","longName":"3121730v1.0:2233077v1.0","context":"CTEP","contextVersion":"2.31","ObjectClass":{"publicId":"3121730","version":"1","preferredName":"Blood Coagulation","preferredDefinition":"Blood circulating throughout the body.:The process of clot formation. (from On-line Medical Dictionary)","longName":"C12434:C20812","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Blood","conceptCode":"C12434","definition":"A liquid tissue; its major function is to transport oxygen throughout the body. It also supplies the tissues with nutrients, removes waste products, and contains various components of the immune system defending the body against infection. Several hormones also travel in the blood.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Coagulation","conceptCode":"C20812","definition":"The process of clot formation. (from On-line Medical Dictionary)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8B6A7F53-484A-0AD5-E040-BB89AD433968","latestVersionIndicator":"Yes","beginDate":"2010-07-15","endDate":null,"createdBy":"ALAIS","dateCreated":"2010-07-15","modifiedBy":"ONEDATA","dateModified":"2010-07-15","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2233077","version":"1","preferredName":"Assessment","preferredDefinition":"The final result of a determination of the value, significance, or extent of.","longName":"C25367","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Assessment","conceptCode":"C25367","definition":"The final result of a determination of the value, significance, or extent of.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F90B5E56-BAFE-0F45-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-06-08","modifiedBy":"ONEDATA","dateModified":"2005-06-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008551","version":"1","preferredName":"Assessments","preferredDefinition":"evaluations of the patient and the patient's disease.","longName":"ASSESS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22DA727-6718-5A2D-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"GOG CRF:Gynecologic Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"8B6A7F53-4858-0AD5-E040-BB89AD433968","latestVersionIndicator":"Yes","beginDate":"2010-07-15","endDate":null,"createdBy":"ALAIS","dateCreated":"2010-07-15","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3298541","version":"1","preferredName":"Yes No Not Applicable Code Indicator","preferredDefinition":"Indicator to represent a response of Yes, No, or Not Applicable._The affirmative response to a question or activity._The non-affirmative response to a question._Determination that a value is not relevant in the current context._A system of numbered categories for representation of data.","longName":"YES_NO_NA_CD_IND","context":"CCR","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":"1","maxLength":"1","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"X","valueDescription":"Not applicable","ValueMeaning":{"publicId":"2581003","version":"1","preferredName":"Not applicable","longName":"2581003v1.00","preferredDefinition":"Determination of a value is not relevant in the current context.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Not Applicable","conceptCode":"C48660","definition":"Determination of a value is not relevant in the current context.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0978-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-12-31","endDate":null,"createdBy":"SBREXT","dateCreated":"2003-12-31","modifiedBy":"CLOHNES","dateModified":"2023-11-09","changeDescription":null,"administrativeNotes":"2023.3.6 Added Alt VM-COG. ak","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B04AC04D-C223-0627-E040-BB89AD432C31","beginDate":"2002-02-11","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"ONEDATA","dateModified":"2011-10-27","deletedIndicator":"No"},{"value":"N","valueDescription":"No","ValueMeaning":{"publicId":"2559515","version":"1","preferredName":"No","longName":"2559515","preferredDefinition":"The non-affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"No","conceptCode":"C49487","definition":"The non-affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B588-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"GDEEN","dateModified":"2024-01-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B04AC04D-C22D-0627-E040-BB89AD432C31","beginDate":"2002-08-22","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"ONEDATA","dateModified":"2011-10-27","deletedIndicator":"No"},{"value":"Y","valueDescription":"Yes","ValueMeaning":{"publicId":"2560453","version":"1","preferredName":"Yes","longName":"2560453","preferredDefinition":"The affirmative response to a question or activity.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes","conceptCode":"C49488","definition":"The affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B932-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"CLOHNES","dateModified":"2023-09-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B04AC04D-C237-0627-E040-BB89AD432C31","beginDate":"2002-08-22","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"ONEDATA","dateModified":"2011-10-27","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008551","version":"1","preferredName":"Assessments","preferredDefinition":"evaluations of the patient and the patient's disease.","longName":"ASSESS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22DA727-6718-5A2D-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"3298540","version":"1","preferredName":"Yes No Not Applicable Code Indicator","preferredDefinition":"The affirmative response to a question or activity.:The non-affirmative response to a question.:Determination that a value is not relevant in the current context.:A system of numbered categories for representation of data.:An event, entity or condition that typically characterizes a prescribed environment or situation and determines or aids in determining whether certain stated circumstances exist or criteria are satisfied.","longName":"3298540v1.0","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes","conceptCode":"C49488","definition":"The affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"No","conceptCode":"C49487","definition":"The non-affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Not Applicable","conceptCode":"C48660","definition":"Determination of a value is not relevant in the current context.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Code","conceptCode":"C25162","definition":"A symbol or combination of symbols which is assigned to the members of a collection.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Indicator","conceptCode":"C25180","definition":"An event, entity or condition that typically characterizes a prescribed environment or situation and determines or aids in determining whether certain stated circumstances exist or criteria are satisfied.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B04AC04D-C1F2-0627-E040-BB89AD432C31","latestVersionIndicator":"Yes","beginDate":"2011-10-27","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"ONEDATA","dateModified":"2011-10-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"CTMS:Clinical Trials Monitoring Service","workflowStatus":"RELEASED","registrationStatus":"Application","id":"B04AC04D-C203-0627-E040-BB89AD432C31","latestVersionIndicator":"Yes","beginDate":"2011-10-27","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"MAESKEB","dateModified":"2016-01-20","changeDescription":"Created to support Theradex design of CRFs for NCI CCR trials","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"3876352","version":"1","longName":"Inclusion Criteria","context":"Theradex","ClassificationSchemeItems":[{"publicId":"3876425","version":"1","longName":"Laboratory Data (including serologic/viral status)","context":"Theradex"}]},{"publicId":"3876594","version":"1","longName":"Theradex","context":"Theradex","ClassificationSchemeItems":[{"publicId":"3876603","version":"1","longName":"Theradex - CTMS 3.14","context":"Theradex"}]}],"AlternateNames":[{"name":"LAB_BLD_COAG_COD_IND","type":"USED_BY","context":"Theradex"}],"ReferenceDocuments":[{"name":"Theradex - 2","type":"Alternate Question Text","description":"Are pre-study prothrombin time (PT)/International normalized ratio (INR) and partial thromboplastin time (PTT) less than or equal to 1.3 x institutional ULN?  Patients receiving anticoagulation treatment may be allowed to participate with INR established within the therapeutic range prior to randomization.","url":null,"context":"Theradex"},{"name":"Theradex - 4","type":"Alternate Question Text","description":"Are pre-study Prothrombin time (PT)/International normalized ratio (INR) and partial thromboplastin time (PTT) less than or equal to 1.2 x institutional ULN?","url":null,"context":"Theradex"},{"name":"Theradex - 1","type":"Alternate Question Text","description":"Are pre-study prothrombin time (PT)/International normalized ratio (INR) and partial thromboplastin time (PTT) less than or equal to 1.5 x institutional upper limit of normal?","url":null,"context":"Theradex"},{"name":"Theradex - 5","type":"Alternate Question Text","description":"Is pre-study International Normalized Ratio (INR) or Prothrombin Time (PT) less than or equal to 1.5 x ULN unless subject is receiving anticoagulant therapy not requiring laboratory monitoring as long as PT or PTT is within therapeutic range of intended use of anticoagulants?","url":null,"context":"Theradex"},{"name":"Is pre-study INR less than or","type":"Preferred Question Text","description":"Is pre-study INR less than or equal to 1.5 x upper limit of normal or PT less than or equal to 1.5 x upper limit of normal seconds above control unless patient is currently receiving warfarin therapy for the treatment or prevention of venous thrombosis?","url":null,"context":"Theradex"},{"name":"Theradex - 3","type":"Alternate Question Text","description":"Is pre-study INR less than or equal to 1.4?","url":null,"context":"Theradex"},{"name":"Theradex - 9","type":"Alternate Question Text","description":"Is pre-study prothrombin time (PT)/International Normalized Ratio (INR) or partial thromboplastin time (PTT) test greater than or equal to 1.3 x the laboratory upper limit of normal within 7 days prior to the first dose of study treatment?","url":null,"context":"Theradex"},{"name":"Theradex - 8","type":"Alternate Question Text","description":"Is pre-study INR less than 2?","url":null,"context":"Theradex"},{"name":"Theradex - 7","type":"Alternate Question Text","description":"Is pre-study PTT less than or equal to 40 seconds unless due to lupus coagulant?","url":null,"context":"Theradex"},{"name":"Theradex - 6","type":"Alternate Question Text","description":"Are pre-study PT/INR and PTT less than 1.3 x upper limit of normal?","url":null,"context":"Theradex"},{"name":"Theradex - 10","type":"Alternate Question Text","description":"Is pre-study prothrombin time or INR less than or equal to 1.5 x upper limit of normal?","url":null,"context":"Theradex"},{"name":"Theradex - 12","type":"Alternate Question Text","description":"Is pre-study INR less than or equal to 2?","url":null,"context":"Theradex"},{"name":"Theradex - 13","type":"Alternate Question Text","description":"Are pre-study Activated Partial Thromboplastin Time (aPTT) and PT less than or equal to 1.2 x ULN?","url":null,"context":"Theradex"},{"name":"Theradex - 11","type":"Alternate Question Text","description":"Is pre-study prothrombin time or INR and PTT less than or equal to 1.3 x upper limit of normal?","url":null,"context":"Theradex"},{"name":"Theradex - 14","type":"Alternate Question Text","description":"Are pre-study coagulation parameters (INR, aPTT) within 1.25 x institutional upper limit of normal, unless a Lupus anti-coagulant has been confirmed?","url":null,"context":"Theradex"},{"name":"Theradex - 17","type":"Alternate Question Text","description":"Are pre-study PT/INR and PTT less than or equal to 1.5 x upper limit of normal?","url":null,"context":"Theradex"},{"name":"Theradex - 15","type":"Alternate Question Text","description":"Are pre-study coagulation parameters within 1.25 x institutional upper limit of normal, unless a Lupus anti-coagulant has been confirmed or except patients on anticoagulation?","url":null,"context":"Theradex"},{"name":"Theradex - 16","type":"Alternate Question Text","description":"If patient is not receiving therapeutic anticoagulation, are pre-study INR and aPTT less than or equal to 1.5 x upper limit of normal?","url":null,"context":"Theradex"},{"name":"Theradex - 19","type":"Alternate Question Text","description":"Is pre-study INR less than or equal to 1.4 unless the patient is receiving therapeutic doses of Coumadin?","url":null,"context":"Theradex"},{"name":"Theradex - 20","type":"Alternate Question Text","description":"Is pre-study prothrombin time (PT)/International Normalized Ratio (INR) or partial thromboplastin time (PTT) test greater than or equal to 1.5 x the laboratory upper limit of normal within 7 days prior to the first dose of study treatment?","url":null,"context":"Theradex"},{"name":"Theradex - 22","type":"Alternate Question Text","description":"Are pre-study aPTT and PT less than to 1.2 x upper limit of normal?","url":null,"context":"Theradex"},{"name":"Theradex - 25","type":"Alternate Question Text","description":"Are pre-study prothrombin time (PT) or partial thromboplastin time (PTT) less than 1.5 x upper limit of normal (ULN), OR International normalized ratio (INR) less than 1.5?","url":null,"context":"Theradex"},{"name":"Theradex - 23","type":"Alternate Question Text","description":"Are pre-study coagulation parameters (INR and aPTT) within 1.25 x institutional upper limit of normal, unless a Lupus anti-coagulant has been confirmed?","url":null,"context":"Theradex"},{"name":"Theradex - 21","type":"Alternate Question Text","description":"Are pre-study prothrombin time (PT)/International normalized ratio (INR) and partial thromboplastin time (PTT) less than or equal to 1.5 x institutional ULN unless patient is on anticoagulant therapy?","url":null,"context":"Theradex"},{"name":"Theradex - 24","type":"Alternate Question Text","description":"If receiving patient is receiving warfarin, is INR less than or equal to 3.0 without any evidence of active bleeding within 14 days prior to first dose of study treatment?","url":null,"context":"Theradex"},{"name":"Theradex - 26","type":"Alternate Question Text","description":"Is pre-study prothrombin time (PT) or partial thromboplastin time (PTT) less than 1.5 x upper limit of normal (ULN), OR International normalized ratio (INR) less than 1.5?","url":null,"context":"Theradex"},{"name":"Theradex - 28","type":"Alternate Question Text","description":"If patient is receiving warfarin, is INR less than or equal to 3.0 without any evidence of active bleeding within 14 days prior to first dose of study treatment?","url":null,"context":"Theradex"},{"name":"Theradex - 29","type":"Alternate Question Text","description":"Are pre-study aPTT and PT greater than or equal to 1.2 x upper limit of normal?","url":null,"context":"Theradex"},{"name":"Theradex - 30","type":"Alternate Question Text","description":"Are pre-study aPTT and PT less than or equal to 1.2 x upper limit of normal?","url":null,"context":"Theradex"},{"name":"Theradex - 31","type":"Alternate Question Text","description":"Are pre-study coagulation parameters (INR and aPTT) within 1.25 x institutional upper limit of normal, unless a Lupus anti-coagulant has been confirmed or except pateints on anticoagulants?","url":null,"context":"Theradex"},{"name":"Theradex - 33","type":"Alternate Question Text","description":"Are pre-study prothrombin time (PT)/International normalized ratio (INR) and partial thromboplastin time (PTT) less than or equal to 1.3 x institutional upper limit of normal?","url":null,"context":"Theradex"},{"name":"Theradex - 32","type":"Alternate Question Text","description":"Are pre-study international normalized ratio (INR) or prothrombin time (PT) and partial thromboplastin time (PTT) or activated PTT (aPTT) less than or equal to 1.5 x ULN?","url":null,"context":"Theradex"},{"name":"Theradex - 36","type":"Alternate Question Text","description":"Are screening visit International normalized ratio (INR) and aPartial Thromboplastin Time (aPTT) less than or equal to 1.5 x ULN?","url":null,"context":"Theradex"},{"name":"Theradex - 35","type":"Alternate Question Text","description":"Is pre-study PTT or APTT less than or equal to 1.5 x upper limit of normal?","url":null,"context":"Theradex"},{"name":"Theradex - 37","type":"Alternate Question Text","description":"Are pre-study PT and aPTT less than 1.5 x upper limit of normal, unless thought to be related to the underlying disease?","url":null,"context":"Theradex"},{"name":"Theradex - 38","type":"Alternate Question Text","description":"Are both PT and aPTT less than or equal to 1.5 x upper limit of normal?","url":null,"context":"Theradex"},{"name":"Theradex - 39","type":"Alternate Question Text","description":"Are pre-study PT and aPTT less than or equal to 1.5 x upper limit of normal, unless thought to be related to the underlying disease?","url":null,"context":"Theradex"},{"name":"Theradex - 47","type":"Alternate Question Text","description":"Are pre-study prothrombin time (PT)/International normalized ratio (INR) and partial thromboplastin time (PTT) less than 1.3 x ULN?","url":null,"context":"Theradex"},{"name":"Theradex - 40","type":"Alternate Question Text","description":"Is pre-study INR less than or equal to 1.5 x upper limit of normal?","url":null,"context":"Theradex"},{"name":"Theradex - 41","type":"Alternate Question Text","description":"Are pre-study International Normalized Ratio (INR) or Prothrombin Time (PT) and activated partial thromboplastin time (aPTT) less than or equal to 1.5 x ULN unless subject is receiving anticoagulant therapy as long as PT or PTT is within therapeutic range of intended use of anticoagulants?","url":null,"context":"Theradex"},{"name":"Theradex - 27","type":"Alternate Question Text","description":"Are pre-study Prothrombin time (PT) and aPartial Thromboplastin Time (aPTT) less than or equal to 1.5 x upper limit of normal?","url":null,"context":"Theradex"},{"name":"Theradex - 49","type":"Alternate Question Text","description":"If patient is not receiving therapeutic anticoagulation, are International Normalized Ratio (INR) or prothrombin time (PT) or activated partial thromboplastin time (aPTT) less than or equal to 1.5 x upper limit of normal OR if patient is receiving therapeutic anticoagulation is patient on a stable dose?","url":null,"context":"Theradex"},{"name":"Theradex - 48","type":"Alternate Question Text","description":"Is pre-study INR and PTT less than or equal to 1.5 x upper limit of normal?","url":null,"context":"Theradex"},{"name":"Theradex - 50","type":"Alternate Question Text","description":"If patient is therapeutically treated with anticoagulation including warfarin, is the patient`s medication dose and INR/PTT stable?","url":null,"context":"Theradex"},{"name":"Theradex - 51","type":"Alternate Question Text","description":"Are pre-study international normalized ratio (INR) or prothrombin time (PT) and partial thromboplastin time (PTT) or activated PTT (aPTT) less than or equal to 1.5 x ULN, unless patient is on a stable dose of anti-coagulation therapy which will be allowed to participate if they have no signs of bleeding or clotting and the INR/PT and PTT/aPTT results are compatible with an acceptable risk-benefit ratio as per the investigator's discretion?","url":null,"context":"Theradex"},{"name":"Theradex - 55","type":"Alternate Question Text","description":"Is pre-study prothrombin time (PT) or partial thromboplastin time (PTT) less than 1.5 x upper limit of normal (ULN), OR is International normalized ratio (INR) less than 1.5?","url":null,"context":"Theradex"},{"name":"Theradex - 56","type":"Alternate Question Text","description":"Are pre-study PT and PTT within the institutional normal limits?","url":null,"context":"Theradex"},{"name":"Theradex - 57","type":"Alternate Question Text","description":"Is International normalized ratio (INR)/Prothrombin time (PT) and either partial thromboplastin or activated partial thromboplastin time (aPTT) less than or equal to 1.5 × ULN?","url":null,"context":"Theradex"},{"name":"Theradex - 59","type":"Alternate Question Text","description":"Are prothrombin time (PT)/International normalized ratio (INR) and partial thromboplastin time (PTT) less than or equal to 1.3 x institutional ULN?","url":null,"context":"Theradex"},{"name":"Theradex - 60","type":"Alternate Question Text","description":"Is pre-study INR less than 1.5?","url":null,"context":"Theradex"},{"name":"Theradex - 58","type":"Alternate Question Text","description":"Is pre-study activated partial thromboplastin time (aPTT) less than or equal to 1.5 x ULN unless patient is receiving anticoagulant therapy as long as PT or PTT is within therapeutic range of intended use of anticoagulants?","url":null,"context":"Theradex"},{"name":"Theradex - 61","type":"Alternate Question Text","description":"If patient is enrolled to the atezolizumab + bevacizumab combination arm, is International normalized ratio (INR) greater than or equal to 1.5 (or greater than therapeutic range if patient is receiving warfarin),  PTT greater than or equal to 1.5 x ULN?","url":null,"context":"Theradex"},{"name":"Theradex - 62","type":"Alternate Question Text","description":"Are pre-study International Normalized ratio  (INR)/Prothrombin time (PT) and activated partial thromboplastin time (aPTT) less than or equal to 1.5 x ULN within 14 days of randomization/enrollment?","url":null,"context":"Theradex"},{"name":"Theradex - 34","type":"Alternate Question Text","description":"Are pre-study PT/INR and aPTT within 1.25 x institutional upper limit of normal, unless a Lupus anti-coagulant has been confirmed or the patient is on direct oral anticoagulant (DOA)?","url":null,"context":"Theradex"},{"name":"Theradex - 63","type":"Alternate Question Text","description":"Is INR and either PTT or aPTT less than or equal to 1.5 x ULN?","url":null,"context":"Theradex"},{"name":"Theradex - 52","type":"Alternate Question Text","description":"Is pre-study International Normalized Ratio (INR) less than or equal to 1.5 and no clinically significant bleeding event within the past six months?","url":null,"context":"Theradex"},{"name":"Theradex - 64","type":"Alternate Question Text","description":"If patient is not receiving therapeutic anticoagulation, are pre-study PT/aPTT less than or equal to 1.5 x ULN?","url":null,"context":"Theradex"},{"name":"Theradex - 53","type":"Alternate Question Text","description":"Are pre-study International Normalized Ratio (INR) or Prothrombin Time (PT) and activated partial thromboplastin time (aPTT) less than or equal to 1.5 x ULN unless subject is receiving anticoagulant therapy as long as PT or PTT is within therapeutic range of intended use of anticoagulants, within 3 days prior to the first day of 7+3?","url":null,"context":"Theradex"},{"name":"Theradex - 67","type":"Alternate Question Text","description":"Are pre-study INR or PT and aPTT less than or equal to 1.5 x ULN unless patient is receiving anticoagulant therapy as long as PT or PTT is within therapeutic range of intended use of anticoagulants?","url":null,"context":"Theradex"},{"name":"Theradex - 66","type":"Alternate Question Text","description":"Are pre-study PTT (or aPTT) and INR less than or equal to 1.5 institutional ULN (except for patients receiving anticoagulation therapy)?","url":null,"context":"Theradex"},{"name":"Theradex - 65","type":"Alternate Question Text","description":"Are pre-study prothrombin time (PT) and partial thromboplastin time (PTT) less than or equal to 1.5 x upper limit of normal (ULN)?","url":null,"context":"Theradex"},{"name":"Theradex - 68","type":"Alternate Question Text","description":"If patient is not receiving therapeutic anticoagulation that may affect INR, are International Normalized ratio (INR)/Prothrombin time (PT) and activated partial thromboplastin time (aPTT) less than or equal to 1.5 x upper limit of normal, within 14 days of enrollment?","url":null,"context":"Theradex"},{"name":"Theradex - 69","type":"Alternate Question Text","description":"Is pre study International normalized ratio (INR) or prothrombin time (PT): less than or equal to 1.5 x ULN unless patient is receiving anticoagulant therapy as long as PT or PTT is within therapeutic range of intended use of anticoagulants?","url":null,"context":"Theradex"},{"name":"Theradex - 70","type":"Alternate Question Text","description":"Is pre-study INR less than or equal to 1.5 x ULN unless participant is receiving anticoagulant therapy, in which case PT or aPTT should be within expected therapeutic range of anticoagulants?","url":null,"context":"Theradex"},{"name":"Theradex - 71","type":"Alternate Question Text","description":"If patient is not receiving therapeutic anticoagulation are INR and aPTT less than or equal to 1.5 x ULN or if patient is receiving therapeutic anticoagulation, such as low-molecular-weight heparin or warfarin, patient is on a stable dose?","url":null,"context":"Theradex"}],"origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"FD3B5F10-787D-5EEF-E040-BB89AD4330C9","latestVersionIndicator":"Yes","beginDate":"2014-07-02","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-07-02","modifiedBy":"SOKKERL","dateModified":"2023-09-05","changeDescription":"Theradex_ghd_07-02-14 03-09-2018 Changed Theradex 25 and 26 to lower case x DW","administrativeNotes":"2023.6.23 Special character corrected per ticket request CADSR0002546. ak 7/26/2022: fixed the symbol x in AQTs per ticket #.CADSR0001349.wz 7/20/2022: fixed the box symbol in AQT.wz","unresolvedIssues":null,"deletedIndicator":"No"}}